20
Participants
Start Date
February 29, 2004
Primary Completion Date
February 28, 2005
Study Completion Date
November 30, 2005
anti TNFa monoclonal antibody - Infliximab
Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
placebo
Placebo
University Hospital Gasthuisberg, Leuven
KU Leuven
OTHER